CareDx (CDNA) Misses Q3 EPS by 4c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. TSLA
6. META
7. RTX
8. SMCI
9. GOOGL
10. S

Go back to CareDx (CDNA) Misses Q3 EPS by 4c

CareDx, Inc. Reports Third Quarter 2015 Financial Results

November 11, 2015 4:05 PM EST

BRISBANE, Calif., Nov. 11, 2015 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value, non-invasive surveillance solutions for transplant recipients, today reported financial results for the third quarter ended September 30, 2015.

Recent highlights:

Total revenues for the third quarter were $7.2 million, a year-over-year increase of 7% Significant progress on AlloSure, the company's transplant surveillance solution under development based on cfDNA technology: The DART clinical trial, an observational study designed to demonstrate the clinical performance characteristics of cell-free DNA... More